Effects of menadione on 1,2-dimethylhydrazine-induced mouse colon adenocarcinoma.
The effects of menadione (Vit K3) administered at 20 or 40 mg.kg-1 ig 3 times a week for both 24 and 28 wk on 1,2-dimethylhydrazine (DMH)-induced mouse colon adenocarcinomas were investigated. At the 24th wk, the number of colon tumors in Vit K3 20 or 40 mg.kg-1 group (0.3 +/- 0.5 and 0.5 +/- 0.8, respectively) was less than that of DMH controls (2.1 +/- 2.5, P < 0.05), but the difference in incidence of colon tumors in these 3 groups was not significant (P > 0.05). After 28 wk, the tumor incidence of both Vit K3 groups (each 8 of 13) was lower than that of DMH controls (13 of 13, P < 0.05); the number of colon tumors of Vit K3 40 mg.kg-1 group (1.3 +/- 1.3, P < 0.05) was decreased, whereas the Vit K3 20 mg.kg-1 group (3.0 +/- 5.1, P > 0.05) was not different from the DMH controls (7.3 +/- 9.3). Determination of the nuclear DNA content of cells from DMH-induced mouse colon mucosa (24 wk) indicated that Vit K3 20 or 40 mg.kg-1 group showed lower DNA content (1.92 +/- 0.12 C and 1.91 +/- 0.10 C, respectively) decreased values of percent-over-3C and -4C and narrow distribution range. Besides, the colon mucosa of DMH-treated mice (28 wk) showed higher superoxide dismutase (SOD) activity (70 +/- 28 U/mg protein, P < 0.05) than the normal controls (30 +/- 20 U/mg protein). Vit K3 40 mg.kg-1 reduced the elevated SOD activity markedly (44 +/- 23 U/mg protein, P < 0.05).
Bi
S
S
Department of Pharmacology, Zhejiang Medical University, Hangzhou, China.
Geng
B Q
BQ
Yong
D G
DG
D000230:Adenocarcinoma / Q000139:chemically induced / Q000517:prevention & control*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D004273:DNA, Neoplasm / Q000032:analysis; D004127:Dimethylhydrazines; D005260:Female; D007413:Intestinal Mucosa / Q000737:chemistry / Q000201:enzymology; D051379:Mice; D008813:Mice, Inbred ICR; D013482:Superoxide Dismutase / Q000378:metabolism; D014812:Vitamin K / Q000031:analogs & derivatives* / Q000627:therapeutic use; D024483:Vitamin K 3
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004127:Dimethylhydrazines; D014812:Vitamin K; D024483:Vitamin K 3; D013482:Superoxide Dismutase